Home » Emerging technologies » DNA synthesis » News Digest #208 – IDT’s $1.9b Acquisition! Melinda Gates on Tech Meets Bio

News Digest #208 – IDT’s $1.9b Acquisition! Melinda Gates on Tech Meets Bio


Hi all,

Big news for Integrated DNA Technologies: this week, the company was acquired by Danaher for an estimated amount of $1.9 billion. IDT will operate as a standalone operating company and brand within Danaher’s Life Sciences platform.

Melinda Gates recently shared her views in an interview at SXSW 2018. She recognizes the power of biotechnology: “We are just on the tip of the cusp of where we might go.” Read more here.

In other news, Atomwise raised $45 Million in a Series A round to become the preferred artificial intelligence partner for pharmaceutical, biotech, and agrochemical companies. Check out Abraham Heifets’ presentation at SynBioBeta SF 2017 starting at 36:44. OxSyBio has secured £10m in Series A financing to further develop its artificial cell platform and 3D bioprinting technology to create therapeutic tissues for patients.

Y Combinator updated their request for startups to include cellular agriculture and clean meat, carbon removal technologies, cleaner commodities, and longevity and anti-aging. Kat Manalac will be speaking at SynBioBeta 2018, register by March 31st to get a discount.

MD Anderson and Berkeley Lights launched Optera Therapeutics to develop cell therapies for cancer, and Emily Leproust was featured by the San Francisco Chronicle. “What happened over the years in making transistors from silicon, we’re doing the same thing with DNA,” she said. Read more about how DNA could transform the way data is stored, and don’t miss Berkeley Lights and Twist Bioscience at SynBioBeta 2018.

Finally, Autolus, a biopharma company in the UK engineering T-cell therapies for cancer, filed for a Nasdaq IPO, Their most recent funding was a £59 million Series C, followed by £70 million Series A and B financings.

Enjoy the rest of the week.

An Interview with Scientist Poet Peter Bickerton

“Science is philosophy, philosophy is imagination, imagination is art. They are all one and the same and we should teach that.”

Exploring the Frontiers of Microbiome and Drug Development

Synthetic biology is shaping a new class of microbiome therapeutics based on living medicines.

ExxonMobil and Synthetic Genomics Algae Biofuels Program Targets 10,000 Barrels Per Day by 2025

Program advances to outdoor testing in California of naturally occurring algae strains.

EPA Opens Public Comments for Oxitec’s EUP Application for Friendly™ Mosquitoes

The purpose of Oxitec’s experimental use program is to determine the efficacy of self-limiting Aedes aegypti.

Start-up Biocellection Devours Pollution with New Plastic Recycling Method

It’s estimated only 9% of plastic ever created has been recycled. But with the help of a chemical process, BioCellection wants to change that.

Modern Meadow Partners with Evonik to Grow Fermentation Processes to Commercial Scale

The biofabrication company announced that it will be joining forces with Evonik as it prepares for commercial scale production of its bioleather materials.

Who’s Hiring?

Senior/Staff Computational Scientist, Bioinformatics: Inscripta, Boulder, CO

Sr. Scientist, Applications: Inscripta, Boulder, CO

Assembly Scientist – DNA Script: Paris, France

Enzyme Production Leader – DNA Script: Paris, France

Technology Application Scientist – DNA Script: Paris, France

To feature your job here, please get in touch

All the News

Sofinnova Partners Closes €125M Fund Focused on Industrial Biotechnologies

Bioengineers today emphasize the crucial ingredient Dr. Frankenstein forgot – responsibility (The Conversation)

Corporate bio VCs are backing more rounds and making bigger bets (Tech Crunch)

How CRISPR is transforming drug discovery (Nature)

Cambridge’s first community biology lab opens to new members

Four stories of antibacterial breakthroughs – Old drugs and new tricks keep researchers one step ahead of antibiotic resistance (Nature)

Farmland gene editors want cows without horns, pigs without tails, and business without regulations (MIT Tech Review)

Twist Bioscience Expands North American Presence with Office in San Diego, California (Press Release)

Synlogic Presents Clinical and Preclinical Data from Synthetic Biotic™ Medicine Programs (Press Release)

If you’ve got news to share, please drop me a note.

Copyright © %%current_year_YYYY%%, All rights reserved.

1547 Palos Verdes Mall, #411
Walnut Creek, CA 94597

About Us | Update Preferences | Unsubscribe | View email in your browser

Click here to join our weekly newsletter. We want to hear what you think about this article. Got a tip for our news team? Write to editorial@synbiobeta.com.

Editor’s picks